An announcement from Imugene Limited ( (AU:IMU) ) is now available.
Imugene Limited has announced that its allogeneic CAR T-cell therapy, azer-cel, has been granted Fast Track Designation by the FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This designation is expected to accelerate the development and review process, potentially improving patient access to this promising therapy. Azer-cel, which uses pre-manufactured donor T-cells, aims to overcome challenges associated with autologous CAR T therapies, such as manufacturing delays and limited patient access. Clinical trials have shown promising results, with a manageable safety profile and no instances of immune effector cell-associated neurotoxicity syndrome. This development positions Imugene as a key player in addressing critical unmet needs in the treatment of aggressive non-Hodgkin’s lymphoma.
More about Imugene Limited
Imugene Limited is a clinical-stage immuno-oncology company focused on developing innovative therapies for cancer treatment. The company specializes in creating allogeneic CAR T-cell therapies, targeting serious conditions such as diffuse large B-cell lymphoma (DLBCL), with a market focus on addressing unmet medical needs in oncology.
YTD Price Performance: 5.00%
Average Trading Volume: 156,986
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $171.5M
See more data about IMU stock on TipRanks’ Stock Analysis page.